Inovio Pharma (INO)
$0.59
0.03 (4.39%)
INO Stock Quote Delayed 30 Minutes
Inovio Has Little to Show for Its Covid-19 Efforts
Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
11 Best Stocks to Buy for 2023
INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
124.72M
PE Ratio
-1.14
EPS
-0.52
Volume (Avg. Vol.)
776,455
Day's Range
$0.59 - $0.63
52-Week Range
$0.58 - $2.82
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
Avoid Inovio Pharmaceuticals Stock Until the FDA Greenlights Trials
While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.
Inovio Investors Need FDA to Write Positive Prescription for Stock Gains
The bad news is that the FDA recently halted the Inovio trial. Think about that for a moment. The world is in dire of need of a Covid-19 vaccine and the U.S. is engaged “Operation Warp Speed” to get a vaccine to market, but here's a regulator telling Inovio to pump the brakes.
The FDA’s Questions Aren’t a Deal Breaker for Inovio Stock
INO stock is down but not out as the development of a Covid-19 vaccine is bound to have some bumps in the road.
Could the FDA Be Ready to Crash Inovio’s Hopes and Dreams?
It’s been a month since the FDA put Inovio’s Covid-19 vaccine on partial clinical hold. No news is definitely not good news for INO stock.
Time Is Running Out on Inovio as Other Vaccine Candidates Advance
The FDA's latest decision has dealt a killer blow to INO stock, which was already struggling to keep up with Big Pharma in the vaccine race.
Investors Should Buy the Phase II/III Dip in Inovio
INO stock is in a rough spot of late, but it is poised to bounce back from these temporary setbacks with a strong product portfolio.
Why the FDA’s Inquiry of Inovio Is More Critical Than You Think
INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here’s why you should be concerned.
Avoid Inovio Like the Plague After Its 64% Price Drop
INO stock has fallen more than 60% since June and further declines look imminent as the company struggles with its Covid-19 vaccine.
Inovio Stock Is a Great Long Setup for an Overreaction Trade
A freak-out ensued after the FDA placed a halt on Inovio's Covid-19 vaccine trials, but the price dip is a chance to buy INO stock cheaper.
Avoid Inovio Pharmaceuticals Like the Plague
The pharma is pursuing a Covid-19 vaccine. But INO stock is risky as the company has failed to bring a product to market for 40 years.
Inovio Pharmaceuticals Does Not Need Any More Misfortune
INO stock is plummeting after the FDA put a hold on its INO-4800 vaccine candidate. But by the time Inovio resumes the trial, will a vaccine be needed?
Don’t Count Out Inovio Pharmaceuticals Stock Just Yet
INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA.
Trump Coronavirus News: Why the Market Is Sliding Today
The market is sliding on today on Trump coronavirus news following confirmation that President Donald Trump tested positive.
This Latest FDA Hold Is a Crushing Blow for Reeling Inovio Stock
Inovio has lost the race for a novel coronavirus vaccine. And INO stock could plummet, given increasing doubts about the company as a whole.
How to Decide if Inovio Is a Buy After Its 28% Correction
Inovio Pharmaceuticals fell 28% after the FDA put a partial clinical hold on vaccine trial. Should you buy INO stock on the dip?
All Hope Is Not Lost for Inovio Pharmaceuticals Stock
Trends come and trends go, but INO stock is coming back but innovation never goes out of style. Hold on trials hurts, but doesn't kill yet.
Inovio Pharmaceuticals News: INO Stock Slammed 28% by Pause in Covid-19 Vaccine Trial
Inovio Pharmaceuticals (INO) news for Monday includes the pausing of its vaccine trial for the novel coronavirus sending INO stock lower.
Inovio Stock Still Has Real Promise Despite Faltering in Vaccine Race
INO stock lost steam due to delays in the next stage of its vaccine trials, but there are plenty of reasons why it's still a worthwhile bet.
Speculate on Inovio and Covid-19 Vaccine Developers
After bottoming at $10 earlier this month, investor interest soared in the last week for INO stock and the company's DNA medicine.
